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Abstract
Postoperative cognitive dysfunction (POCD) and postoperative delirium (POD) are of
concern in the elderly population undergoing an anesthetic due to increased mortality and
decreased quality of life that can ensue. Sui et al. (2021) reported a 15-50% incidence of POD in
elderly surgical patients. Dexmedetomidine is a highly selective, alpha-2 agonist with sedative,
analgesic, and anxiolytic properties that mimics a sleep-like state and causes bradycardia and
hypotension but not respiratory depression. Dexmedetomidine has neuroprotective properties,
including anti-apoptosis and anti-inflammation (Wu et al., 2019). A current review of the
literature revealed that dexmedetomidine use can decrease POD incidence in the aged patient
population undergoing general anesthesia. Intraoperative or postoperative dexmedetomidine use
should be considered in the elderly patient receiving general anesthesia.
keywords: delirium, postoperative delirium, postoperative cognitive dysfunction, elderly,
aged, dexmedetomidine
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The Impact of Dexmedetomidine Use in Patients Over the Age of 60 Undergoing
General Anesthesia on Postoperative Delirium Incidence
Delirium is the most common postoperative complication in the elderly, with an incidence
of up to 54% (American Geriatrics Society Expert Panel on Postoperative Delirium in Older
Adults, 2015; Li et al., 2020; Subramaniyan &Terrando, 2019). Implications of delirium are
serious and impact the patient, their families, healthcare givers, and society. Oh et al. (2017)
reported that delirium is responsible for an annual cost of 164 billion United States dollars, and it
affects over 2.6 million patients per year. Dexmedetomidine has been used successfully to decrease
emergence delirium in pediatric patients, prompting worthwhile research into its use in the adult
and aged populations (Li et al., 2020). Dexmedetomidine has been shown to decrease delirium,
improve sleep quality in adults admitted to the intensive care unit (ICU) after surgery, and improve
quality of life, cognitive function, and long-term survival at a three-year follow-up (Wu et al.,
2019).
This paper will discuss what delirium is, how it is assessed, its implications, how surgery
and anesthesia contribute to delirium development, and known interventions to decrease delirium.
A brief overview of POD, POCD, and dexmedetomidine will follow. A literature review of the
effect of dexmedetomidine use in elderly patients undergoing surgery and its effects on
postoperative delirium was performed. The literature search was conducted several times using
PubMed, Embase, and Cochrane Collection Plus databases through the University of New England
access. A review of the literature sought out original studies and systematic reviews with metaanalyses examining POD or POCD incidence when dexmedetomidine was used perioperatively in
the aged population, identified as people over the age of 60. Several articles examining
neurocognitive disorders, the pharmacology of dexmedetomidine, its role as a neuroprotective
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agent, and strategies in preventing and treating POD or POCD were also included. Ten original
trials and 12 systematic reviews with meta-analyses published in 2016 or later were included in
this literature review to examine relevant findings for meaningful implications for clinical practice
for our aging population. Articles solely examining postoperative dexmedetomidine use,
evaluating dexmedetomidine as a secondary agent in combating POD, studies in which POD was a
secondary outcome, and those with neuraxial anesthesia as the primary anesthetic were excluded.
The literature focused on methods of dexmedetomidine administration, cardiac versus noncardiac
surgery types, and outcomes of dexmedetomidine use in the elderly population undergoing
surgery.
Delirium
What is Delirium?
Delirium involves acute changes in the patient's level of consciousness, awareness,
attention, memory, and recognition. Variations in the patient’s assessment and sleep-wake cycle
disturbances are common in delirium. Neurotransmitter imbalance affects cortical and subcortical
activity, including that at the reticular activating system, playing a role in the symptoms seen in
delirium (Migirov et al., 2021). The inflammatory cascade elicited by surgery could impact the
brain’s cognitive functioning contributing to the symptoms seen in delirium (Zeng et al., 2019).
Genetics, neurotransmitter levels, electrolyte, and/or metabolic imbalances can also be implicated
in the development of delirium (Zeng et al., 2019). Hypoactive, hyperactive, and mixed types of
delirium exist (Deiner et al., 2017; Janssen et al., 2019; Qin et al., 2021; Migirov et al., 2021;
Vlisides & Avidan, 2019). Hypoactive delirium is seen as a lethargic state and is often
underdiagnosed in more than half of the actual cases (American Geriatrics Society Expert Panel on
Postoperative Delirium in Older Adults, 2015; Janssen et al., 2019; Migirov et al., 2021).
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Hypoactive delirium appears with slowed alpha waves on EEG studies (Migirov et al., 2021;
Vlisides & Avidan, 2019). Delirium is not diagnosed in 60% of the cases by the patient's primary
caregivers but rather by "expert assessors" such as psychiatrists, geriatricians, neurologists, and
those providers with extensive training in delirium assessment (Oh et al., 2017, p. 1161). This
inaccurate assessment could be due to the constraints of standardized screening tools, especially
when utilized once per day. Oh et al. (2017) indicated that patient interviews and chart reviews
will increase the sensitivity and specificity of diagnosing delirium. Postoperative delirium onset
can occur within hours to days after surgery. Because of the timing of the inflammatory processes
during surgery, POD primarily presents two to three days postoperatively, causing the
neurocognitive changes seen in delirium (Lee et al., 2018). Postoperative delirium can be
diagnosed within a week of surgery or before discharge per the criteria in the Diagnostic and
Statistical Manual of Mental Disorders (DSM), fifth edition (Wang et al., 2021)
Postoperative cognitive dysfunction encompasses changes in cognition affecting memory,
mood, communication, and sleep. This dysfunction presents after anesthesia and can last for weeks
to months. Where delirium is a temporary state, POCD is longer lasting. Postoperative cognitive
dysfunction implications can vary from prolonged hospitalization to difficulty communicating,
decreased intelligence, personality change, self-care limitation, and it can lead to Alzheimer's
disease (Carr et al., 2018; Yang et al., 2019; Zhou et al., 2016). Diagnosis of POCD is difficult due
to the slow onset, its variation in symptoms, and the lack of standard criteria (Wu et al., 2019). The
incidence of POCD is estimated to be 10-12% (Yang et al., 2019). Liu et al. (2015) shared that
38% of patients with acute delirium had a diagnosis of Alzheimer's disease two years later. Van
Norden et al. (2021) contributed that 25% of patients diagnosed with delirium will experience
symptoms comparable to those of mild Alzheimer’s disease, and that up to 70% of elderly patients
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over the age of 65 years who have experienced postoperative delirium will have an eventual
diagnosis of dementia.
Screening Tools for Delirium
Many studies included in this literature review utilized the Confusion Assessment
Method (CAM) or CAM modified for the intensive care unit (CAM-ICU) screening tool to assess
patients for delirium. The CAM is a standardized, well-accepted, and widely used screening tool.
Liu et al. (2015) and Oh et al. (2017) detailed the CAM-ICU assesses patients for delirium using
the following data categories: altered mental status from baseline, inattention, disorganized
thinking, and an altered level of consciousness. The patient must screen positive for the first two
criteria listed and either disorganized thinking or an altered level of consciousness for a positive
diagnosis utilizing this tool. Despite the common use and acceptance of the CAM, Vlisides and
Avidan (2019) pointed out that CAM and CAM-ICU are inferior to "expert-based delirium
identification" (p. 3). Vlisides and Avidan (2019) further revealed that these experts may differ on
their delirium assessment, possibly stemming from the inconsistencies found in different editions
of the DSM. These authors shared a study that found delirium was diagnosed in only 30% of the
cases when the DSM-IV criteria were used versus the updated DSM-V criteria (Vlisides &Avidan,
2019). In addition to this diagnostic discrepancy, the authors identified potential gaps in educating
healthcare workers on the appropriate screening tools and the implementation of delirium
management protocols. This potential area for improvement in staff education highlights the
concern that delirium is not being adequately identified and, therefore, may be potentially
underreported and undertreated.
Oh et al. (2017) provided that the CAM has a high sensitivity, specificity, and interrelated
reliability. Halpin et al. (2020) cited a 95% sensitivity and an 89% specificity for the CAM-ICU
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tool. Janssen et al. (2019) performed a systematic review and meta-analysis including 31
randomized control trials (RCTs) and four before and after studies looking at prevention strategies
for POD prevention in elderly patients. Over half of the studies included in Janssen et al. (2019)
utilized CAM to assess the participants for delirium. Lee et al. (2019) validated CAM-positive
patients with a psychiatrist’s diagnosis. Lin et al. (2021) identified 21 RCTs evaluating the use of
dexmedetomidine for delirium prevention in elderly patients over the age of 60 undergoing various
types of surgery. Each of these reviewed studies utilized the CAM or CAM-ICU. Qin et al. (2021)
performed a systematic review and meta-analysis of 13 RCTs studying the effect of perioperative
dexmedetomidine use on delirium prevention in adults over 18 undergoing noncardiac surgery.
Each of these RCTs utilized the CAM or CAM-ICU assessment to screen for delirium like the
majority of the articles included in this literature review. The CAM and CAM-ICU screening tool
remains a standardized, well-known, and frequently used assessment method for delirium in
healthcare settings.
The Mini- Mental State Exam (MMSE) was utilized in 13 studies analyzed by Carr et al.
(2018) and it was determined that this tool inaccurately identified dementia, particularly in
outlying patient populations, including the aged, less educated, and those with different cultural
backgrounds. Zhang et al. (2018) identified the MMSE is best used for serious cognitive
dysfunction, and assesses the patient on orientation, memory, calculation, language, visual-spatial
ability application, and attention. The higher the score on the MMSE, the less severe the cognitive
impairment. The MMSE is used to screen patients for cognitive impairment but was initially
created to assess cognitive deficits in the patient with an established diagnosis of dementia
(Migirov et al., 2021). The MMSE excluded patients with underlying cognitive dysfunction in Li
et al. (2021). Deiner et al. (2017) assessed the participants in their study using the CAM-ICU
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screening tool in the recovery room to assess for POD but also utilized the Delirium Symptom
Interview in conjunction with the MMSE to assess their participants allowing for higher sensitivity
and specificity and the ability to identify delirium occurrences in between assessments. Zhou et al.
(2016) were interested in participants’ MMSE scores when reviewing studies that measured
intraoperative dexmedetomidine use and the incidence of POCD. Mini-Mental State Exam scores
were measured to determine the severity of POCD in the cardiac and noncardiac studies included
in the systematic review and metanalysis undertaken by Yang et al. (2019).
The Montreal cognitive assessment (MoCA) is best utilized for assessing patients with
mild cognitive dysfunction per Zhang et al. (2018). The MoCA assesses visual space function,
language, attention, calculation, recall, and abstract thinking by patients. Migirov et al. (2021)
shared the MoCA is a more sensitive test than the MMSE in detecting postoperative
neurocognitive disorders per the results of a systematic review and cautioned the reader that the
MoCA does not take into account the patient’s level of education and lacks cultural
generalizability.
Implications of POD and POCD
Postoperative delirium is distressing for the patient, their families, and hospital staff.
Postoperative delirium is associated with increased mortality, prolonged hospital stay, decreased
incidence of returning to independent living, increased healthcare costs, and cognitive and
functional decline (Deiner et al., 2017; Duan et al., 2018; Liu et al., 2016; Pan et al., 2019; Shi et
al. 2019; Vlisides & Avidan, 2019; Xin et al., 2021). Postoperative cognitive dysfunction can
cause changes in memory, impair intellect, impact personality, and the ability to interact with
others and to care for oneself. Postoperative cognitive dysfunction impacts individuals, families,
and society.
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Risk Factors for POD and POCD Development
Delirium is a complex acute state with multiple contributing factors. There is a higher
risk of incidence in patients with preexisting cognitive impairment (Vlisides and Avidan, 2019;
Xin et al., 2021). Additionally, preoperative cognitive function is the most significant factor for
POD risk (Wu et al., 2019). Janssen et al. (2019) identified frailty, advanced age, preexisting
cognitive deficits, malnutrition, polypharmacy, pain, length of stay, blood loss, preoperative
anemia, indwelling urinary catheters, and type of surgery as predisposing risk factors for delirium
development. In general, cardiac surgery and the use of the cardiopulmonary bypass machine
increases the risk of postoperative neurocognitive deficits (Duan et al., 2018; Migirov et al., 2021).
Inadequate pain control contributes, as does the use of morphine due to its neurotoxic properties
(Shi et al., 2019).
The risk factors for POCD are similar to those for POD. Advanced age, delirium
duration, preexisting cognitive impairment, type and duration of surgery, return to the operating
room, postoperative infection, mechanical ventilation, hypertension, the use of benzodiazepines,
and educational level are risk factors for POCD development (Yang et al., 2019; Zhou et al.,
2016). Zhou et al. (2016) identified that cardiac surgery has been definitively linked to increased
incidence of POCD, whereas hypotension, depth of anesthesia, and elevated cortisol levels have
been postulated to impact increased incidence directly. Liu et al. (2016) identified that lengthy
periods of POD have been linked to POCD development. Conversely, regional anesthesia has been
associated with decreased incidence of POCD (Zhou et al., 2016).
Known Interventions to Decrease Delirium
Numerous authors agree that prevention is necessary with our aging population and the
high incidence of POD and POCD. Janssen et al. (2019) revealed that 30 to 40% of delirium cases
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are preventable, and once delirium sets in, treatment does very little to decrease the duration,
severity, or recurrence. It is imperative to mitigate preventable risk factors, including pain
management, utilization of sensory devices, and optimizing nutritional status and sleep schedule.
Janssen et al. (2019) performed a systematic review looking at studies that had an intervention to
decrease POD. Thirty-one RCTs and four before and after trials were analyzed. The authors
categorized the findings according to the phase of care along the perioperative continuum that the
intervention was performed. Conclusively, several strategies, including the use of multicomponent
interventions like the Hospital Elder Life Program (HELP), antipsychotic medications, anesthesia
depth guided by bispectral index (BIS), and the use of dexmedetomidine, were successful in
decreasing POD incidence.
Vlisides and Avidan (2019) described similar effective management strategies in three
significant trials looking at anesthetic depth and postoperative delirium. In the Cognitive
Dysfunction after Anesthesia (CODA) trial, a BIS guided anesthetic depth in 902 participants
undergoing general anesthesia with either inhaled agents or propofol. In this landmark trial
conducted by Chan et al. (2013), the randomly assigned BIS-guided group was compared to a
standard care, control group in which the patients had a BIS in place for data collection, but
providers were unaware of this BIS data. Participants’ neurocognitive function was assessed one
week before surgery, one week after surgery, and three months postoperatively. Patients were
assessed daily with the CAM for delirium. There was a 35% decrease in delirium incidence during
hospitalization and a 31% decrease in POCD three months after surgery in the BIS-guided group.
Furthermore, anesthetic depth guided by a BIS to a level of 40 to 60 resulted in a 20% reduction in
propofol dose delivery and a 30% reduction in volatile anesthetic administration (Chan et al.,
2013).
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In the second referred study, the Surgery Depth of Anaesthesia and Cognitive Outcome
trial, 1277 elderly patients undergoing noncardiac surgery with volatiles or propofol were either
BIS-guided or BIS-blinded. There was a 16.5% incidence of POD in the BIS-guided compared to
21.4% in the BIS-blinded group. Vlisides and Avidan (2019) pointed out early trial conclusion was
due to a lack of funding, and a portion of the BIS-blinded group was unblinded for some part of
the study. Despite these limitations, Vlisides and Avidan (2019) indicated that this study, along
with the CODA trial, supports the thought that EEG suppression and deep anesthesia are
associated with POD. Li et al. (2020) presented this correlation between deep anesthesia and an
increased likelihood of delirium incidence and inferred that a decreased level of anesthesia could
be achieved using a BIS. Vlisides and Avidan (2019) described the Electroencephalopathy
Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) trial looked particularly at
avoiding EEG suppression in BIS-guided participants versus BIS-blinded participants. This trial
did not support the notion that deep anesthesia is a direct causative factor for POD, as delirium
occurred in more patients who received BIS monitoring and adjusted anesthesia than in the control
group. In line with the ENGAGES trial, the Strategy to Reduce the Incidence of Postoperative
Delirium in Elderly Patients trial looked at aged patients undergoing hip surgery and POD
incidence in light and heavy sedation combined with spinal anesthesia. There was no difference in
POD based on the level of sedation received (Vlisides & Avidan, 2019). The American Geriatrics
Society Expert Panel on Postoperative Delirium in Older Adults (2015) detailed an inadequate
amount and low-quality evidence on the using a BIS guiding a low anesthetic depth and its direct
effect on POD incidence. Despite these two trials, the consensus in the literature is that the risk of
delirium could be decreased when the least amount of adequate anesthesia is administered (Janssen
et al., 2019; Oh et al., 2017). Migirov et al. (2021) and the American Geriatrics Society Expert
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Panel on Postoperative Delirium in Older Adults (2015) recognized the utilization of EEG device
assisted anesthetic monitoring in guiding anesthetic depth but caution against the risk of light
anesthesia consequences, concern for overreliance on BIS or EEG indices as single data points, as
well as the lack of long-term results of EEG-guidance on postoperative cognitive function, thus
encouraging the need for further, more definitive research.
Multicomponent interventions like the HELP involve multiple disciplines that employ
strategies to preserve functional status and cognition in hospitalized elderly patients. The American
Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults detailed
multicomponent nonpharmacological interventions such as promoting mobility and sleep quality,
visual and auditory aids, optimizing fluid and nutritional status, pain management, and avoidance
of infection and hypoxia. Vlisides and Avidan (2019) reported decreased POD incidence and
healthcare costs with the HELP utilization based on a meta-analysis of 14 studies. Janssen et al.
(2019) reviewed six studies that implemented a multicomponent intervention program similar to
the HELP, four of which decreased delirium incidence.
Oh et al. (2017) conducted a literature search on delirium diagnosis and treatment from
2011 to 2017. This article included guidelines targeting the prevention and the treatment of POD in
the elderly in the perioperative period released by the American Geriatric Society and the
American College of Surgeons in 2014. Oh et al. (2017) detailed seven strong recommendations,
the following: (1) appropriate continuing education for healthcare staff, (2) pre-assessments
performed to identify potential risk factors for delirium, (3) multicomponent nonpharmacological
interventions for patients at risk for delirium, and (4) adequate analgesia planning with emphasis
on nonopioid medications. Furthermore, (5) antipsychotics and benzodiazepines should be avoided
in the hypoactive delirium patient, and (6) agitation should not be initially treated with
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benzodiazepines in patients with delirium. The last recommendation (7) included avoidance of
medications that can contribute to delirium, including anticholinesterases, opioids,
benzodiazepines, antihistamines, dihydropyridines (Oh et al., 2017). Weak recommendations
included using regional anesthesia when possible to decrease postoperative pain and delirium and
the use of the lowest possible effective dose of antipsychotic medications for the shortest possible
time in delirious patients who are a risk to themselves or others. Lastly, multicomponent
nonpharmacological interventions can be used to prevent POD and treat the patient who has
already been diagnosed with POD (American Geriatrics Society Expert Panel on Postoperative
Delirium in Older Adults, 2015; Oh et al., 2017). Ultimately, Oh et al. (2017) urged that
preventing and managing delirium with a multicomponent nonpharmacologic approach is the
safest and most effective strategy.
Inflammatory Response to Surgery Effects
Lee et al. (2018), Li et al. (2020), Migirov et al. (2021), Zeng et al. (2019), Zhang et al.
(2018), and Zhou et al. (2016) recognized the role of inflammation from anesthesia and surgery on
the development of POD and POCD. There is evidence that brain interleukin (IL-6), tumor
necrosis factor (TNF-⍺), and S100 ß protein are increased by anesthesia and surgery (Zhang et al.,
2018). Activated IL-6 and TNF-⍺ are adaptive and innate immunity cytokines associated with the
hyperactive form of delirium (Migirov et al., 2021). Surgical stress increases cortisol production,
which in turn causes IL-6 release. Lee et al. (2018) measured IL-6 levels in participants older than
age 65 undergoing laparoscopic surgery at one and 24 hours after surgery, finding significantly
lower levels in those who received dexmedetomidine versus those who received saline. Lee et al.
(2018) postulated that patients who received dexmedetomidine were less likely to develop POD
because of this decreased inflammatory response finding. Govêia et al. (2021) cited several other
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research articles in which dexmedetomidine decreased IL-6 and TNF-⍺ levels supporting
dexmedetomidine’s anti-inflammatory properties. Zhang et al. (2018) identified S100 ß protein as
an indicator of central nervous system injury, and elevated levels were correlated to brain injury
and could be associated with POCD incidence. Govêia et al. (2021) connected that
dexmedetomidine’s neuroprotective qualities were attributed to its ability to decrease S100 ß
protein and neuron-specific enolase levels, thereby protecting the patient from postoperative
cognitive and behavioral dysfunction.
Dexmedetomidine Pharmacology
Multiple authors, including Carr et al. (2017), Liaquat et al. (2021), and Yang et al.
(2019) described dexmedetomidine as a selective alpha-2 adrenergic agonist that has sedative,
analgesic, anxiolytic, and sympatholytic effects. Dexmedetomidine decreases sympathetic nervous
system activity, potentially causing bradycardia and hypotension. This drug causes a dosedependent decrease in catecholamine release in the central nervous system. Sedation occurs in the
locus coeruleus (Yang et al., 2019). Dexmedetomidine creates a stage two, sleep-like state where
respiratory function is preserved, and the patient remains arousable. Dexmedetomidine allows for
decreased opioid consumption because of its action at the alpha-2 adrenergic receptor (Carr et al.,
2018; Govêia et al., 2021; Pan et al., 2019).
Carr et al. (2018), Nagelhout & Elisha (2018), and Liaqat et al. (2021) detailed that alpha-2
receptors are G-protein coupled receptors that when activated, decrease the production of adenylyl
cyclase, and in turn decrease the amount of cyclic adenosine monophosphate (CAMP) available,
therefore leading to a decrease in cell excitability. Activation of the G-protein coupled receptors
hyperpolarizes the cell via the opening of potassium channels, accounting for a decrease in protein
and catecholamine release. Calcium influx is inhibited by G protein-coupled receptor activation
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which limits protein kinase C formation, decreasing its contribution to oxidative stress and
apoptosis. Dexmedetomidine’s action at the presynaptic neuron decreases the release of the
neurotransmitter norepinephrine. Dexmedetomidine produces a dose-dependent sedative effect and
decrease in BIS values. Dexmedetomidine does not impact cerebral metabolism but causes
cerebral vasoconstriction, lowering cerebral blood flow (Nagelhout & Elisha, 2018).
Dexmedetomidine is a short-acting sedative with an onset of action of 10 to 20 minutes, a
distribution half-life of six minutes, and a 10 to 30-minute duration of action when stopped.
Dexmedetomidine is metabolized by the liver and excreted in the kidneys relatively unchanged and
is highly protein-bound (Nagelhout & Elisha, 2018). Dexmedetomidine regulates
neuroinflammation, apoptosis, oxidative stress, and synaptic plasticity, providing neuroprotective
properties. Dexmedetomidine works centrally in the medulla oblongata to decrease the
sympathetic nervous system response, thus impacting the neuroendocrine stress response to
surgery (Carr et al., 2018). This mechanism also decreases shivering (Nagelhout & Elisha, 2018).
As discussed above, the body’s inflammatory response to surgical stress can be mitigated by
dexmedetomidine’s neuroprotective effects (Govêia et al., 2021; Lee et al., 2018; Zhang et al.,
2018).
Literature Review
Dexmedetomidine and POD
Noncardiac Surgeries
Dexmedetomidine and its impact on POD were studied in several well-designed RCTs in
elderly patients undergoing noncardiac types of surgery. Five of the six original RCTs showed
intraoperative dexmedetomidine decreased the incidence of POD. Saline was used in the control
group of five original trials examining intraoperative dexmedetomidine administration (Deiner et
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al., 2017; Lee et al., 2018; Li et al., 2020; Liu et al., 2016; Xin et al., 2021). One RCT, conducted
by Zhang et al. (2018), compared an anesthetic consisting of dexmedetomidine with either
propofol or sevoflurane to an anesthetic consisting of midazolam with either propofol or
sevoflurane. Of these five original trials that showed that intraoperative dexmedetomidine
decreased the incidence of POD, one by Liu et al. (2016) and the other by Xin et al. (2021) solely
investigated patients with baseline mild cognitive impairment (MCI), while Deiner et al. (2017)
included patients with baseline MCI in their study. Delirium assessment was performed either
twice per day on postoperative days one through five or on postoperative days one, three, and
seven in all original studies except that performed by Denier et al. (2017) validating the results.
In a landmark trial, Deiner et al. (2017) conducted a ten-center, double-blinded, parallelgroup, placebo-controlled RCT involving 404 patients over 68 years old undergoing major
noncardiac surgery. This trial utilized dexmedetomidine on arrival to the operating room (OR) and
continued the infusion until two hours postoperatively, whereas the control group received saline.
The authors assessed the patient’s preoperative cognitive function, assessed for POD with the
CAM or CAM-ICU, performed a three month follow up, and performed a six month follow up to
compare cognitive scores to baseline scores. There was no difference in severity between groups or
subtypes of delirium. In fact, the incidence of POD was the same in both the control and study
groups. In this study, there was a relationship in patients with lower education status and baseline
MCI to POD, but not with POCD. Dexmedetomidine administration had no impact on
postoperative cognitive outcomes at three and six months postoperatively. This original trial was
cited by or included in the systematic review and meta-analyses by Duan et al. (2018); Lee et al.
(2018); Li et al. (2020); Lin et al. (2021); Pan et al. (2019); Qin et al. (2021); Xin et al. (2021); van
Norden et al. (2021); Zeng et al. (2019); and Wang et al. (2021). These other authors are critical of
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this original study by Denier et al. (2017) as POD was only assessed once per day and initially
began in the post anesthesia care unit (PACU).
Li et al. (2020) performed a double-blind RCT involving 260 patients over 60 years old
undergoing major noncardiac surgery. Participants were randomized to receive either a loading
dose of dexmedetomidine before induction followed by continuous infusion until one hour before
the end of the surgery or participants received volume matched normal saline. The CAM or CAMICU was used to assess patients for POD during the first five days postoperatively. A BIS was
utilized intraoperatively to guide anesthetic depth, and anesthesia was maintained with intravenous
(IV) propofol, sufentanil, and 1:1 oxygen to nitrous oxide. Dexmedetomidine halved the risk of
POD in adults over the age of 60 years undergoing major noncardiac surgery. Dexmedetomidine
was associated with a lower rate of acute agitation, perioperative tachycardia, early postoperative
nausea and vomiting (PONV), and non- delirium complications 30 days after surgery. A morphine
PCA was used postoperatively in this study, a distinction that is important as opioids have been
shown to contribute to POD incidence and severity.
Cardiac Studies
Three original RCTs in elderly patients undergoing cardiac surgery were found and
included in this review. In the double-blinded, randomized, placebo-controlled, multi-center trial
conducted by Li et al. (2017), 285 adults over the age of 60 years undergoing elective coronary
artery bypass grafting (CABG) and/or valve replacement received either dexmedetomidine or
saline initiated at 0.6 mcg/kg over 10 minutes then 0.4 mcg/kg/hr until the end of the case. After
surgery, the medication was continued at 0.1 mcg/kg/hr. Patients could receive preoperative
medications, and general anesthesia was maintained with either total intravenous anesthesia
(TIVA) consisting of sufentanil and propofol, or with sevoflurane, both methods with a target BIS
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of 40-60. All patients went to the ICU postoperatively, and those requiring mechanical ventilation
were sedated with propofol infusions titrated to the Richmond Agitation Sedation Scale (RASS)
score of - 2 to + 1. Preoperatively, patients were screened via the MMSE, Hospital Anxiety and
Depression Scale, and the Barthel Index. Delirium was assessed in the morning on postoperative
days one through five with the CAM or CAM-ICU. The patient’s RASS, pain, and sleep quality
were also assessed.
On postoperative day six, MMSE was redone, secondary outcomes recorded, and on
postoperative day 30, telephone interviews were done with the Chinese version of Telephone
Interview for Cognitive Status (m-TICS). Li et al. (2017) found no significant difference between
the two groups regarding the incidence of delirium during the first five days postoperatively (4.7%
in the dexmedetomidine group and 7.7% in the control group). Mini- mental state examinations
and m-TICS scores on postoperative day 30 were similar between the two groups. There were no
significant differences in the overall incidence of non-delirium complications within 30 days and
all-cause 30-day mortality. Pain intensity and subjective sleep quality were similar in both groups.
However, in the dexmedetomidine group, the duration of mechanical ventilation was shorter and
there were fewer pulmonary complications. As previously identified, anesthetic depth has been
related to POD incidence. Because the BIS-guided anesthetic depth resulted in a lower BIS value
in the dexmedetomidine group than in the control group, the results of POD incidence may be
skewed. This study could have had more participants as there was a low incidence of delirium in
the control group. Li et al. (2017) excluded patients with preexisting risk factors for delirium,
preventing the generalizability of the results. This study found an increased incidence of
hypotension in patients receiving dexmedetomidine, as did the metanalysis of noncardiac surgeries
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by Pan et al. (2019) and the metanalysis of both cardiac and noncardiac surgeries performed by Lin
et al. (2021).
Shi et al. (2019) conducted a double-blinded, multiple center RCT of 64 elderly patients
undergoing cardiac surgery with TIVA. The patients in the experimental group received 0.4-0.6
mcg/kg/hr of dexmedetomidine with remifentanil, propofol, and cisatracurium, whereas the control
group received remifentanil, propofol, and cisatracurium, but did not receive dexmedetomidine. A
Sedline brain function monitor that displays and processes four EEG waveforms and provides an
index number like the BIS was used in all cases. The primary outcome was POD incidence within
the first five postoperative days. The patients were assessed with the CAM twice daily, once in the
morning and again in the evening. The Visual Assessment Scale (VAS), a pain measurement scale,
was used to rate their pain. All patients received a morphine containing PCA postoperatively. The
researchers collated the average morphine consumption and 24-hour VAS scores over the five
postoperative days. A psychiatrist validated the delirium diagnosis. Shi et al. (2019) found no
statistical difference in POD incidence between the two groups as POD occurred in 33 patients
who received propofol only and 21 of the patients who received dexmedetomidine. The authors did
find a decreased duration of delirium and observed a one-day, delayed onset of POD in the patients
who received dexmedetomidine versus propofol. An important limitation of this study is the small
population size and that no evaluations of the patient's preexisting mental state were included. It is
essential to remember that inadequate analgesia contributes to POD incidence, as does morphine.
Likhvantsev et al. (2021) recognized the mixed findings of dexmedetomidine’s use on
POD in cardiac surgery and conducted a single center, double blind, RCT in 169 patients over the
age of 45 undergoing cardiac surgery on cardiopulmonary bypass. Patients in the experimental
group received an infusion of dexmedetomidine at 0.7 mcg/kg/hr started on induction which was
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continued through the surgery into the postoperative period, where it was titrated to the patient’s
needs until mechanical ventilation was weaned. The control group received saline, but if patients
in the control group required POD management in the ICU, the primary provider would be
unblinded as the study’s primary endpoint was reached, and propofol would be utilized.
Sevoflurane was used as the general anesthetic in both groups. The CAM-ICU was used to assess
patients for POD twice per day starting on postoperative day one through day five. The authors
found a decreased incidence in POD in the dexmedetomidine group, six out of 84, versus the
control, 16 out of 85 participants. There was no difference in the duration of POD between the
groups. The severity of delirium was less in the dexmedetomidine group but only by one point on
the Intensive Care Delirium Screening Checklist. Mechanical ventilation duration and duration in
the ICU and the hospital were reduced in the dexmedetomidine group (Likhvantsev et al., 2021).
Halpin et al. (2020) performed a systematic review of 12 studies that were either RCT,
observational or retrospective studies, or meta-analyses with at least one delirium assessment tool
used. Eleven of the 12 studies had statistically significant evidence of decreased POD incidence
with dexmedetomidine use. The original RCT conducted by Shi et al. (2019) was one of the
studies included in this review and was identified as having a decreased POD incidence despite the
original article deeming it was clinically insignificant as the difference in POD incidence was 12
participants. Halpin et al. (2020) recognized that the overall evidence indicated dexmedetomidine
decreased POD in patients undergoing cardiac surgery but suggested that dexmedetomidine be
used on a case-by-case basis until more evidence is collected in large, multi-center RCTs. This
review included retrospective studies with larger populations but less control and prospective
studies with smaller populations but higher control. Studies included a variety of independent
variables. Two studies did not report how often delirium was assessed or who performed the
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assessment. Four studies did not definitively disclose the pain management strategy used. There is
a lack of definitive dexmedetomidine administration timing in this review by Halpin et al. (2020),
however, the included study titles reveal some perioperative and some postoperative use of
dexmedetomidine. The reviewer can glean that postoperative use is encouraged per the authors’
conclusion.
Wu et al. (2018) performed a systematic review and meta-analysis of 10 RCTs where 1387
participants aged 35-76 underwent cardiac surgery. These studies included the use of
dexmedetomidine compared to saline or another drug, including midazolam, propofol, or
remifentanil where the primary endpoint was POD. Three studies utilized dexmedetomidine
intraoperatively into the postoperative period and six administered only dexmedetomidine
postoperatively. This review found a generalized result of a significant (54%) decrease in POD
incidence in the patients who received dexmedetomidine. Wu et al. (2018) urged early
dexmedetomidine administration before or on arrival to the ICU for optimal delirium prevention.
Li et al. (2021) conducted a systematic review and metanalysis of 15 studies comprising
2,813 patients undergoing CABG or mixed CABG with valve replacement surgeries. Five of the
studies included used dexmedetomidine intraoperatively whereas 10 started dexmedetomidine on
chest closure and continued it through the duration of mechanical ventilation or at least for 24
hours after surgery. Overall results revealed specific conditions in which dexmedetomidine could
reduce the risk of POD. Li et al. (2021) found postoperative dexmedetomidine administration in
the adult population, but not in the aged population over the age of 65, decreased POD compared
to other sedative medications but not when dexmedetomidine was compared to normal saline.
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Administration Timing
Intraoperative
Of the 10 original studies included in this literature review that utilized intraoperative
dexmedetomidine administration, seven showed a statistical difference in POD incidence. Of the
three that did not, one was in noncardiac surgeries by Deiner et al. (2017) and two in cardiac
surgeries (Li et al., 2017; Shi et al., 2019). Li et al. (2021) suggested the neurological insult from
endothelial damage, blood brain barrier changes, cerebral blood flow changes, and microemboli
from the use of the cardiopulmonary bypass may account for the increased POD incidence in
cardiac surgical patients. These physiologic insults could be the reason that despite its
neuroprotective and anti-inflammatory properties, dexmedetomidine was not effective in
significantly decreasing POD in two original cardiac studies as well as two metanalyses in this
literature review. Otherwise, the remainder of the original studies and systematic reviews and
metanalyses revealed dexmedetomidine could decrease POD incidence.
Postoperative
Due to the search and inclusion criteria of the literature review, only systematic reviews
and meta-analyses included studies that examined postoperative administration. Pan et al. (2019)
reviewed 11 RCTs, three of which had postoperative dexmedetomidine administration. Qin et al.
(2021) reviewed 13 RCTs, six of which administered dexmedetomidine both intraoperatively and
postoperatively. The other seven were studies in which dexmedetomidine was administered
intraoperatively; four are included in original studies in this literature review (Deiner et al., 2017;
Lee et al., 2018; Li et al., 2020; Liu et al., 2016). Zeng et al. (2019) included six RCTs, and
postoperative dexmedetomidine administration was the mode in two. These authors did not
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differentiate if the administration timing impacted the outcome of decreased incidence of POD
with dexmedetomidine use.
Duan et al. (2018) examined 18 RCTs in which three included 2,180 patients who
received dexmedetomidine postoperatively, three involved intraoperative use, and three examined
its use both intraoperatively and postoperatively. Dexmedetomidine use exclusively in the
intraoperative or postoperative period revealed a significant decrease in POD incidence but not
when dexmedetomidine was used intraoperatively and postoperatively, which the authors referred
to as the perioperative period. Ten of the 21 RCTs in the review by Lin et al. (2021) used
dexmedetomidine postoperatively. Lin et al. (2021) also found that intraoperative and
postoperative administration of dexmedetomidine resulted in decreased POD incidence but no
difference was found when dexmedetomidine was administered both during and after the surgery,
identified as perioperative use by the authors. Half of the 14 RCTs in cardiac and noncardiac
surgeries reviewed and analyzed by Wang et al. (2021) observed a significant decrease in POD
incidence when dexmedetomidine was administered postoperatively compared to intraoperative or
perioperative use. This timing method and findings are in-line with the findings of Halpin et al.
(2020), Li et al. (2021), and Deiner et al. (2017). In a meta-analysis and systematic review by Li et
al. (2021) that included 15 RCTs where adults had undergone cardiac surgery: postoperative rather
than intraoperative administration of dexmedetomidine had a significant effect in decreasing the
incidence of POD and only had this effect in adults who were not elderly. Correspondingly, early
administration of dexmedetomidine either at the end of the case or on arrival to ICU is
recommended by Wu et al. (2018) in cardiac cases for optimal POD incidence reduction.
Similarly, original research by Deiner et al. (2017) in patients undergoing noncardiac surgery
urged consideration for dexmedetomidine administration timing to be focused postoperatively due
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to previous research revealing POD incidence decreased when dexmedetomidine was used in the
postoperative period rather than propofol or benzodiazepines.
Studies Investigating POCD
Yang et al. (2019) explored the role of dexmedetomidine and inflammation in POCD in
patients undergoing general anesthesia by systematically reviewing and meta-analyzing 26 RCTs
in which dexmedetomidine or a placebo or comparable medication was administered either in a
bolus or infusion before and during anesthesia. All but one of these studies took place in China
utilizing the MMSE to assess patients for POCD. Of note, four of the RCTs did not report the age
of the subjects and three studies included participants between the ages of 13 to 40 years. Surgery
types included laparoscopic, general, orthopedic, cancer, lumbar, urologic, gynecological, and one
surgery involving heart valves. The authors analyzed these studies according to POCD incidence
reporting on postoperative days one, three, and seven, MMSE scores, inflammatory marker levels,
and type of surgery. Yang et al. (2019) concluded that dexmedetomidine lowered the incidence of
POCD in all major surgery types except for orthopedic surgery. In discussion, Yang et al. (2019)
shared a study that showed inflammation in the hippocampus impacted memory in mice
undergoing orthopedic surgery, supporting concerns about the insult that surgery inflicts with the
inflammatory cascade. In this meta-analysis, these authors postulated that dexmedetomidine can
decrease early POCD incidence and lessen the severity given higher MMSE scores found on
postoperative day one. This meta-analysis found improved cognitive function via the MMSE
scores in patients aged older than 60 who received dexmedetomidine with a 95% confidence
interval and a standardized mean difference of 1.69. Lower TNF-⍺ and IL-6, were measured in the
dexmedetomidine versus the control group, solidifying dexmedetomidine’s anti-inflammatory
properties.
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Zhou et al. (2016) performed a meta-analysis on 13 RCTs in patients undergoing general
anesthesia for noncardiac surgery where dexmedetomidine was utilized either as a bolus or an
infusion in the interventional group. The authors were interested in the POCD incidence and
MMSE scores. Postoperative cognitive dysfunction was reported on the first postoperative day in
10 of the 13 studies and was reported thereafter in seven of the 13. The authors found a statistically
significant decreased incidence of POCD in the dexmedetomidine group on postoperative day one,
but not when reported after the first postoperative day. Mini-Mental State Exam scores were
significantly higher on postoperative day one in the dexmedetomidine group than in the control
group, consistent with findings by Yang et al., (2019). Zhou et al. (2016) concluded that
dexmedetomidine can significantly decrease the early incidence of POCD and improve MMSE
scores in the elderly patient undergoing surgery with general anesthesia.
Underlying Mild Cognitive Impairment
Three original studies included or specifically studied patients with baseline MCI. Liu et
al. (2016) described MCI as a state where there is cognitive impairment, but memory is intact,
suggesting MCI occurs as a potential shift between normal aging and Alzheimer’s disease. Deiner
et al. (2017) included patients with underlying MCI in addition to those without any known
cognitive impairment, while Xin et al. (2020) looked at POD incidence in 60 adults with MCI
undergoing laparoscopic cholecystectomy procedures. Liu et al. (2016) studied dexmedetomidine
in the elderly with MCI undergoing knee replacements. Two out of these three studies found a
positive outcome in intraoperative dexmedetomidine use to decrease POD occurrence in the
elderly with preexisting cognitive impairment (Liu et al., 2016; Xin et al., 2021).
Liu et al. (2016) conducted a prospective, randomized, blinded, parallel-group study of 200
adults ages 65-80 years old with an American Society of Anesthesiologists (ASA) score of two or

DEXMEDETOMIDINE USE AND POSTOPERATIVE DELIRIUM

26

three. Eighty adults with baseline amnestic mild cognitive impairment (aMCI) and 120 elderly
adult control patients undergoing total joint replacement were studied. Participants were randomly
assigned to either aMCI dexmedetomidine or aMCI normal saline, a control group with
dexmedetomidine, or a control group with normal saline. Before surgery, all patients received a
neuropsychological assessment, and the CAM tool was used to screen patients for POD on
postoperative days one, three, and seven. Participants in this study received TIVA with propofol
and remifentanil because the authors cited the article that they published in 2013 indicating
sevoflurane speeds up the progression of aMCI after two years. Zhang et al. (2018) identified via
neuro marker levels that sevoflurane increases inflammation, and that the administration of
dexmedetomidine decreased this inflammation, thus decreasing the risk of developing POD. In this
study, Liu et al. (2016) found that older age in the aMCI group correlated to increased POD,
whereas it did not in the control group, highlighting the risk factor of aging on POD development.
POD incidence in the aMCI group was higher than in the control group. Importantly,
dexmedetomidine did significantly decrease the incidence and duration of POD in the patients with
aMCI at baseline.
The connection between POD, dexmedetomidine’s neuroprotective properties, and
neuroinflammatory markers was explored by Xin et al. (2021) in 60 patients with baseline MCI
undergoing laparoscopic cholecystectomy. Patients were randomized to receive either
dexmedetomidine or normal saline. A bolus of 0.5 mcg/kg of dexmedetomidine was administered
over 10 minutes before induction, and an infusion at 0.4 mcg/kg/hr was continued until 30 minutes
before the end of the case. A BIS goal of 40-60 was used, and medications were titrated based on
hemodynamics. Blood samples were obtained before surgery, before suturing, and 30 minutes after
surgery to measure the level of cytokines: TNF-⍺, IL-10, heme oxygenase-1 (HO-1), matric
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metalloproteinase (MMP-9), and glial fibrillary acidic protein (GFAP) in serum. Patients were
assessed with the three-minute diagnostic interview CAM (3DCAM) tool twice per day for the
first seven days after surgery. Blood level findings included elevated TNF-⍺, IL-10, MMP-9, and
GFAP 30 minutes after surgery compared to those at baseline, indicating surgery increases
inflammatory markers. The control group had higher levels of TNF-⍺, MMP-9, and GFAP and a
lower level of IL-10 than the patients that received dexmedetomidine at the time of suturing and 30
minutes after the surgery. The authors pointed out this finding supported the belief that
dexmedetomidine decreases neuroinflammation, and therefore decreases the risk of POD
development. In this study there was a significant decrease in POD incidence in the patients who
received dexmedetomidine. The incidence of POD was one-third in the control group and only
one-tenth in the dexmedetomidine group.
Neuroinflammatory Markers
Dexmedetomidine modulates the inflammatory response inflicted by surgery,
contributing to a decreased incidence of POD. Two original studies in the elderly receiving general
anesthesia demonstrated this relationship. Zhang et al. (2018) conducted a RCT with 120 patients
ages 65-75 with esophageal cancer who were randomly assigned to one of four groups: midazolam
and propofol (M&P), midazolam and sevoflurane (M&S), dexmedetomidine and propofol (D&P),
or dexmedetomidine and sevoflurane (D&S). Patients in the dexmedetomidine groups received a
loading dose of 1mcg/kg followed by 0.5 mcg/kg/hr infusion. Propofol or sevoflurane was used to
maintain anesthesia. Blood was collected 10 minutes before anesthesia, and on the first, third, and
seventh postoperative days. Levels of IL-6, TNF-⍺, and S100 ß were measured. The MMSE and
MoCA were used to assess the patients one day before surgery and on the first, third, and seventh
postoperative days. Key findings of this study include a relationship between sevoflurane and
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increased POCD incidence as evidenced by significantly lower MMSE and MoCA scores in the
midazolam and sevoflurane group compared to the midazolam and propofol group. In support of
this relationship, plasma IL-6 and TNF-⍺ concentrations were significantly higher in the M&S
group than in the M&P group on postoperative days one, three, and seven. In addition, plasma
S100 ß concentration was higher in the M&S group than in both the M&P group and the D&S
group.
Furthermore, in the study conducted by Zhang et al. (2018), plasma IL-6 and TNF-⍺
concentrations were the lowest in the dexmedetomidine and propofol group and highest in the
midazolam and sevoflurane group at all monitored time points. This finding suggests sevoflurane
released IL-6 and TNF-⍺ but that dexmedetomidine inhibited this release. Additionally, MMSE
and MoCA scores were higher on all three assessments in the dexmedetomidine and sevoflurane
group than in the midazolam and sevoflurane group. The authors concluded that dexmedetomidine
may be efficacious in decreasing the incidence of POCD caused by sevoflurane in the geriatric
population. There was no significant difference between perioperative hemodynamics, time to
recovery for spontaneous breathing, anesthesia emergence, or extubation time among the four
groups (Zhang et al., 2018).
Lee et al. (2018) held a double-blind RCT in which 354 patients over 65 years of age
undergoing laparoscopic major noncardiac surgery under general anesthesia received either a
dexmedetomidine 1 mcg/kg bolus followed by 0.2–0.7 mcg/kg/hr infusion from anesthesia
induction to the end of surgery (group D1), received a 1 mcg/kg bolus of dexmedetomidine
15 minutes before the end of surgery (group D2), or received only saline (group S). The CAM was
used to assess patients preoperatively and at 12-hour intervals until postoperative day five. The
primary outcome measure was the incidence of delirium for five days after surgery. Secondary
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outcomes included the duration of delirium for five days after surgery, and cortisol, C-reactive
protein (CRP), and levels of cytokine TNF-⍺, IL-1β, IL-2, IL-6, IL-8, and IL-10 that were
measured at one and 24 hours after surgery.
In this RCT by Lee et al. (2018) dexmedetomidine allowed for a decreased inflammatory
response to surgery, impacting the incidence of POD. Group D1 had a decreased incidence,
severity, and duration of delirium. Group D2 patients with delirium had a decreased duration
compared with Group S. Duration of the delirium between group D1 and D2 was not significantly
different. Patients with delirium in both group D1 and group D2 who received dexmedetomidine
required less haloperidol than patients in group S. A lower level of IL-6 was noted at one and 24
hours postoperatively in group D1 than in group S. Plasma cortisol levels in groups D1 and D2
were lower than those in group S at one hour postoperatively. These neuromarker level results
support dexmedetomidine’s action as an anti-inflammatory agent, likely contributing to its effect
on decreased POD incidence (Lee et al., 2018).
Hemodynamic Effects
Bradycardia and hypotension are the most common side effects of dexmedetomidine due to
its action as an alpha-2 agonist causing vasodilation (Nagelhout &Elisha, 2018). Bradycardia was
reported as a significant occurrence in nine RCTs investigated by Lin et al. (2021), three RCTs
studied by Pan et al. (2019), three RCTs examined in Zeng et al. (2019), and six RCTs studied by
Qin et al. (2021). Of note, several articles overlap that each systematic review and meta-analysis
included. The cardiac surgery systematic review and meta-analysis done by Wu et al. (2018)
observed significant bradycardia but not hypotension. Weerink et al. (2017) detailed that
hypertension can initially be seen with dexmedetomidine administration as alpha-2 receptors in the
vascular smooth muscles are affected, causing an increase in systematic vascular resistance via
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peripheral vasoconstriction. The baroreceptors are then responsible for the bradycardia seen. After
the initial administration, the endothelial alpha-2 receptors are activated, causing vasodilation, and
thus, hypotension. Hypotension is perpetuated by the decrease in catecholamines from
dexmedetomidine’s action at the presynaptic alpha-2 receptor (Weerink et al., 2017).
Li et al. (2021) discussed that dexmedetomidine’s side effect of hypotension could be the
reason why its use intraoperatively did not have a significant impact on POD reduction in the
elderly population undergoing cardiac surgery. The authors emphasized the increased likelihood of
the elderly to experience hypotension as well as the increased incidence of hypotension in cardiac
surgery. Another consideration is the patient’s preoperative exercise capacity, which is likely to be
lower in the elderly population than in adults under the age of 65, leading to inability to tolerate the
hypotension seen with intraoperative dexmedetomidine infusion. Postoperative dexmedetomidine
use in the elderly after cardiac surgery did decrease POD in this systematic review and metaanalysis supporting the connection between hypotension and POD made by Li et al., 2021. Wu et
al. (2018) suggested that an infusion of dexmedetomidine without a loading dose would allow for
better hemodynamic profiles and still benefit the patient with the decreased incidence of POD.
Opioid Sparing Benefit
Pain and opioid use are known risk factors for the development of delirium (Li et al.,
2020). Dexmedetomidine allows for decreased opioid consumption because of its action at the
alpha-2 adrenergic receptor (Carr et al., 2018; Govêia et al., 2021; Pan et al., 2019; Shi et al.
(2019). Analgesia is produced via dexmedetomidine’s action at the alpha-2 site in the dorsal horn
of the spinal cord, which decreases Substance P release (Govêia et al., 2021).
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Impact on PONV
Patients who received dexmedetomidine as an intraoperative infusion in the original trial
conducted by Li et al. (2020) had less early PONV than the control group who only received
saline. A systematic review and meta-analysis of 14 RCTs by Wang et al. (2021) found that
dexmedetomidine administration may decrease PONV incidence with a low level of evidence.
Several authors make the potential connection that because dexmedetomidine can decrease opioid
consumption, it can thereby decrease PONV (Weerink et al., 2017; Zeng et al., 2019).
Dexmedetomidine also decreased the amount of volatile agent required to produce adequate
anesthesia, which could explain this mechanism of decreased PONV seen with its use
intraoperatively.
Length of Stay
In nine RCTs dexmedetomidine was found to decrease the length of stay in the ICU, and
it was found to decrease the hospital length of stay in 11 of the 21 RCTs in the systematic review
and meta-analysis of cardiac and noncardiac surgeries conducted by Lin et al. (2021). Hospital
length of stay was not affected by dexmedetomidine use in the systematic reviews and metanalyses
conducted by Wang et al. (2021) and Wu et al. (2018), however. The authors of the Duan et al.
(2018) review, which included several of the same studies analyzed by Wang et al. (2021), did not
find a high level of evidence in dexmedetomidine use impacting length of stay in either the ICU or
the hospital. In their systematic review and meta-analysis, Pan et al. (2019) only examined
noncardiac surgeries, which revealed a decrease in hospital length of stay when dexmedetomidine
was used intraoperatively or postoperatively. In the original RCT held by Likhvantsev et al. (2021)
in cardiac surgery patients, both the ICU and the hospital length of stay was decreased in the group
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that received dexmedetomidine. Overall, there is evidence in the literature that dexmedetomidine
use could decrease both the length of stay in the ICU and the hospital.
Duration of POD
Overall, the use of dexmedetomidine has been shown to decrease the duration of POD.
There are mixed findings in the literature, however. No difference in the POD duration was found
in the original RCT in 169 patients undergoing cardiac surgery performed by Likhvantsev et al.
(2021). Six of the 14 RCTs analyzed by Wang et al. (2021) reported that dexmedetomidine use
decreased POD duration by a mean difference of 1.24 days. There was no significant difference in
POD duration in the original study which included on pump cardiac, and major noncardiac
surgeries conducted by van Norden et al. (2021). In the study by Lee et al. (2018), the duration of
POD in the groups who received dexmedetomidine was shorter than the duration of POD in the
group who received saline. However, there was not a significant difference in the duration of POD
between the group who received dexmedetomidine in an infusion throughout the case and the
group who only received a bolus of dexmedetomidine at the end of the case. This study proved that
intraoperative dexmedetomidine use shortened the duration of POD.
Additionally, in the RCT of 64 elderly adults undergoing cardiac surgery, a decreased
duration of delirium and a one-day, delayed onset of POD in the patients who received
dexmedetomidine versus propofol was observed by Shi et al. (2019). Identical findings of
decreased delirium and a one-day, delayed onset of POD were seen in a RCT by Liu et al. (2016)
of patients with underlying symptoms of aMCI undergoing a total joint replacement. Duration of
POD was not reported otherwise in the literature.
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Mortality and Quality of Life
Mortality was assessed in several studies available in the literature. In eight of 14 RCTs,
including cardiac and noncardiac surgeries, Wang et al. (2021) reported that dexmedetomidine use
was associated with decreased mortality. A significant decrease in mortality was seen when
dexmedetomidine was utilized in 10 out of 21 RCTs reviewed by Lin et al. (2021). At the threemonth follow-up in the original trial including cardiac and major abdominal surgery held by van
Norden et al. (2021), none of the patients who received dexmedetomidine had died, but five of the
patients in the control group did. The patients' quality of life scores were similar in both groups at
this three-month postoperative follow-up. Zeng et al. (2019) revealed that dexmedetomidine use
had no significant effect on myocardial infarction or hypoxemia and did not significantly decrease
all-cause mortality risk but decreased stroke incidence in three of the RCTs of noncardiac surgeries
reviewed. Likhvantsev et al. (2021) found no difference in 30-day mortality or major adverse
cardiac or cerebral events between the dexmedetomidine and control group in their original RCT
in cardiac surgery patients.
Discussion of the Literature
Limitations in the Literature
Inclusion Criteria
The evidence was limited in large sample size, multiple-center studies with all-inclusive
participant criteria. Many studies excluded patients with significant co-morbidities such as ASA
physical statuses of four or five, those with end stage renal disease, Parkinson’s disease, any visual
or hearing impairment at baseline, and those with a history of mental health diagnoses or traumatic
brain injuries. As previously noted, three studies in this literature review examined the use of
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dexmedetomidine in patients with baseline cognitive impairment. This research is meaningful in its
recommendations for the elderly population that is living longer and presenting for surgery.
Assessment and Monitoring
The question of consistency in POD assessment monitoring and the lack of follow up to
determine long-term effects of POD are present throughout the literature. Liu et al. (2016)
acknowledged the relationship between POD as a risk factor for POCD and recognized the
importance of studying the long-term effects of POD on dementia and cognitive function.
Systematic review and meta-analysis by Pan et al. (2019) revealed a lack of consistency in POD
assessment timing. Several meta-analyses and RCTs revealed differences in monitoring
frequencies throughout this literature review. Importantly, in the original study by Denier et al.
(2017) that found intraoperative dexmedetomidine did not decrease POD, the authors only
assessed patients for POD once a day and began the assessment in the PACU (Lin et al. 2021; Pan
et al. 2019). The variations in assessment timing could have missed patients with signs of delirium.
Meaningful assessment for POD utilizing the CAM tool twice per day starting on postoperative
day one and conducted through until at least postoperative day five in the original trials by Lee et
al. (2018), Li et al. (2020), van Norden et al. (2021), and Xin et al. (2020) lends strength to the
outcomes and recommendations made in each of these studies.
Timing of Dexmedetomidine Administration
The optimal timing of dexmedetomidine for decreasing the incidence of POD was a theme
throughout the literature. Original studies had some insight. Deiner et al. (2017) believed that
postoperative administration made the difference as their study did not show intraoperative
dexmedetomidine administration decreased POD incidence. Systematic review and meta-analysis
by Li et al (2021) in patients undergoing cardiac surgery revealed postoperative but not
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intraoperative dexmedetomidine use decreased POD in the elderly population. Systematic reviews
and meta-analyses by Duan et al. (2019) and Lin et al. (2021) revealed that intraoperative and
postoperative dexmedetomidine administration decreased POD incidence. Lee et al. (2016)
revealed that intraoperative administration was more effective than a one-time bolus or normal
saline. Through a systematic review and meta-analysis, Pan et al. (2019) found that using a loading
dose of dexmedetomidine did not significantly impact POD incidence outcomes. Govêia et al.
(2021) concluded that the timing of dexmedetomidine administration did not matter as patients
who received dexmedetomidine across 15 RCTs had a decreased incidence of POD compared to
those who did not. This generalization is simple, generous, and has some merit. The decreased
severity of POD outcome in patients who at least received a bolus of dexmedetomidine versus just
saline in the original trial by Lee et al. (2016) aided this generalization made by Govêia et al.
(2021), but the decreased incidence of POD in the group that received a bolus followed by a
continuous infusion of dexmedetomidine supports the argument made by many studies suggesting
calculated administration is optimal. Choosing the administration time is crucial when aiming to
impact POD occurrence.
Future Research
The research is promising; there is sufficient data to suggest the use of dexmedetomidine in
the aged population undergoing general anesthesia with both volatile agents and TIVA. More
studies are on the horizon, including a single-center, double-blinded, placebo-controlled RCT
proposed by Sui et al. (2021). With an aging population, the current evidence in the literature, the
prevalence and consequence of delirium, it is necessary to continue examining dexmedetomidine
use in aged patients undergoing general anesthesia.
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Recommendations
In cardiac surgery, POD incidence is between 37 to 52% and is 5 to 51% in open
abdominal surgery (van Norden et al., 2021). Practical strategies and evidence-based practice
approaches for decreasing POD and POCD incidence are crucial as our population is aging.
Overall, this literature review has revealed that intraoperative and postoperative use of
dexmedetomidine decreased the incidence of POD and POCD when assessed via the CAM tool,
decreased both the duration and severity of POD, improved cognitive functioning scores
postoperatively, decreased opioid consumption, and decreased levels of inflammatory markers.
Intraoperative and postoperative dexmedetomidine administration showed the most consistent
results in terms of decreased POD incidence. A focus on prevention through preoperative
optimization and the use of nonpharmacologic multicomponent approaches is currently a top
treatment strategy for POD (American Geriatrics Society Expert Panel on Postoperative
Delirium in Older Adults, 2015; Oh et al., 2017; Vlisides &Avidan, 2019).
Conclusion
Due to the prevalence of POD and POCD, effective strategies to mitigate their
development are merited in the elderly population undergoing general anesthesia. Postoperative
delirium can cause increased hospital length of stay, increased morbidity and mortality, the decline
of cognition and function, and high healthcare costs. Efforts should be focused on prevention
rather than treatment due to the ineffective nature of decreasing the severity of duration once
delirium has set in (Janssen et al., 2019). Many factors contribute to the development of delirium,
including preexisting cognitive dysfunction, frailty, advanced age, malnutrition, polypharmacy,
pain, hospital length of stay, and type of surgery (Janssen et al., 2019). Anesthetic depth, the
inflammatory cascade, and hypotension have been suggested to impact POD development (Zhou et
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al. 2016). Strategies known to decrease the incidence of POD include the use of
nonpharmacologic multicomponent interventions like the HELP, depth of anesthesia guidance with
a BIS, and the use of dexmedetomidine. Further recommendations include assessing patients for
risk factors to better hone on prevention as well as educating healthcare providers on assessments
for early recognition and treatment to decrease duration and severity (American Geriatrics Society
Expert Panel on Postoperative Delirium in Older Adults, 2015; Oh et al., 2017; Vlisides &Avidan,
2019).
Of the 10 original studies, three did not find a statistically significant decrease in POD
incidence when dexmedetomidine was administered to patients undergoing general anesthesia. Li
et al. (2017) and Shi et al. (2019) assessed POD in patients undergoing cardiac surgery, whereas
Deiner et al. (2017) conducted their trial in patients undergoing major noncardiac surgery. Of note,
there was a small incidence of POD in general in the study by Deiner et al. (2017) and in the
control group researched by Li et al. (2017), suggesting the potential for underpowered studies and
potentially inaccurate results. Several authors point out a significantly short duration of
dexmedetomidine administration in the landmark trial by Denier et al. (2017), where
dexmedetomidine was administered on arrival to the OR through two hours postoperatively.
Of the 12 systematic reviews and meta-analyses included in this literature review, some
of which examined outcomes in patients undergoing both cardiac and noncardiac surgeries and
some only cardiac or noncardiac surgeries, all but two found that dexmedetomidine administration
decreased POD incidence. Both Lin et al. (2021) and Wang et al. (2021) found an inadequate level
of evidence that dexmedetomidine decreased POD in elderly patients undergoing cardiac surgery
through their respective systematic reviews and meta-analyses. Some crossover of included studies
was seen between the two author groups.
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Attention to and the intention of anesthetic planning should focus on prevention and risk
reduction, as anesthesia is a risk factor for POD development (Shi et al., 2019). With an aging
population, anesthetic planning that considers POD and POCD reduction strategies are imperative.
All the systematic reviews and meta-analyses agreed that dexmedetomidine administration in the
elderly receiving general anesthesia decreased the incidence of POD in noncardiac surgery or
could decrease the incidence of POD in cardiac surgery. Most of the literature revealed that
intraoperative dexmedetomidine use decreased POD incidence in the aged population. Some of the
literature recommended postoperative dexmedetomidine use to optimize decreased POD incidence.
Dexmedetomidine use can improve patient outcomes with a reduction in POD and should be
considered when planning an anesthetic in an aged patient.
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